The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Oxford, UK – 1 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement (“the Agreement”) with AstraZeneca UK Ltd (“AstraZeneca”) which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine. This represents an expansion of the original Master Supply and Development Agreement announced between the two companies in September 2020.
The manufacture of COVID-19 vaccines at Oxford Biomedica’s Oxbox facility is expected to complete in the last quarter of 2022, as part of the original commitment. In accordance with the terms of the original agreement and inclusive of revenues for batches already manufactured in the first half of 2022, Oxford Biomedica expects to recognise aggregate revenues of approximately £30 million from AstraZeneca in the current financial year.
Under the new agreement, manufacturing of vaccines at Oxford Biomedica’s world class 84,000 sq. ft manufacturing facility, Oxbox, will be available to AstraZeneca on an as needed basis beyond 2022.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: "I am delighted that our close partnership with AstraZeneca has been extended. I am proud of the work of all our colleagues at Oxford Biomedica that has enabled us to deliver more than 100 million doses of lifesaving COVID-19 vaccine. While contributing to the efforts to fight the pandemic, this has also demonstrated Oxford Biomedica's ability to expand the scope of our innovative process development services and deliver high-performing manufacturing solutions beyond lentiviral vectors. We look forward to continuing to work closely with AstraZeneca and execute on our strategy to become a global leader across all viral vectors, enabling Cell and Gene Therapy companies to deliver their life-changing therapies to patients."
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: email@example.com
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: firstname.lastname@example.org
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.